Jefferies on Cabaletta Bio (CABA): 'We came away from EULAR 2026 update increasingly positive on the wholistic resecel profile'

June 3, 2026 7:31 AM

Jefferies analyst Roger Song reiterated a Buy rating and $14.00 price target on Cabaletta Bio (NASDAQ: CABA).The analyst comments "Bottom ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found